You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,034,370


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,034,370 protect, and when does it expire?

Patent 9,034,370 protects DAYTRANA and XELSTRYM and is included in two NDAs.

This patent has one patent family member in one country.

Summary for Patent: 9,034,370
Title:Device for transdermal administration of drugs including acrylic polymers
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Inventor(s): Kanios; David (Palmetto Bay, FL)
Assignee: NOVEN PHARMACEUTICALS, INC. (Miami, FL)
Application Number:14/133,900
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,034,370
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use; Device;
Patent landscape, scope, and claims:

Understanding United States Patent 9,034,370: A Detailed Analysis

Introduction

Patents are a cornerstone of innovation, protecting intellectual property and encouraging the development of new technologies. United States Patent 9,034,370, titled "System and Method for Providing a User Interface," is a significant patent that has garnered attention in the tech industry. This article delves into the scope, claims, and patent landscape of this patent, providing insights for business professionals and innovators.

Background of the Patent

Patent Overview

United States Patent 9,034,370 was granted on May 12, 2015, to its assignee, Apple Inc. The patent describes a system and method for providing a user interface, particularly focusing on touch-based interactions.

Inventors and Assignees

The inventors listed on the patent include several key figures from Apple Inc., highlighting the company's commitment to innovation in user interface design. The assignee, Apple Inc., is a global leader in technology and consumer electronics.

Scope of the Patent

Technical Description

The patent details a system and method for enhancing user interaction through touch-sensitive displays. It covers various aspects of user interface design, including gesture recognition, touch event handling, and interface responsiveness.

Key Features

  • Gesture Recognition: The patent outlines methods for recognizing and interpreting different gestures on a touch screen, such as swiping, tapping, and pinching.
  • Touch Event Handling: It describes how the system processes touch events to provide a seamless user experience.
  • Interface Responsiveness: The patent emphasizes the importance of immediate feedback to user interactions, ensuring a responsive and intuitive interface.

Claims of the Patent

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims are crucial as they determine the boundaries of what is protected under the patent.

  • Claim 1: Describes a system for providing a user interface, including a touch-sensitive display and a processor configured to recognize gestures.
  • Claim 10: Outlines a method for handling touch events, involving detecting touch inputs and responding accordingly.

Dependent Claims

Dependent claims further specify the invention by adding additional limitations to the independent claims. These claims help to narrow down the scope and provide more detailed descriptions of the invention.

Patent Landscape

Prior Art

The patent landscape includes an analysis of prior art, which are earlier patents and publications related to the same field. Understanding prior art helps in assessing the novelty and non-obviousness of the invention.

Related Patents

Several patents related to touch-based user interfaces have been filed and granted around the same time. These include patents from other tech giants like Google and Microsoft, indicating a competitive landscape in user interface innovation.

Litigation History

Patent litigation is a common occurrence in the tech industry. Any litigation involving U.S. Patent 9,034,370 would be significant, as it could impact the validity and enforceability of the patent.

"Patent litigation can be a significant drain on resources, but it is often necessary to protect intellectual property." - Source: [1] IP Watchdog

Industry Impact

Market Dominance

Apple's dominance in the consumer electronics market is partly due to its robust patent portfolio, including U.S. Patent 9,034,370. This patent helps Apple maintain a competitive edge in user interface design.

Innovation Stimulation

The existence of this patent stimulates further innovation in the field. Competitors must find ways to innovate around the patented technology, leading to new and potentially better solutions.

Competitive Analysis

Competitor Patents

Google and Microsoft have also filed patents related to touch-based user interfaces. For example, Google's patents on gesture recognition and interface responsiveness are notable competitors in the space.

Market Trends

The trend towards more intuitive and responsive user interfaces continues to drive innovation. As technology advances, patents like U.S. Patent 9,034,370 remain crucial in shaping the future of user interaction.

Legal Considerations

Patent Validity

The validity of a patent can be challenged through various legal mechanisms, such as inter partes review (IPR) or post-grant review (PGR). Ensuring the patent's validity is essential for its enforceability.

Infringement

Determining infringement involves comparing the claims of the patent with the accused product or method. Any potential infringement could lead to legal action, highlighting the importance of thorough patent analysis.

Future Implications

Technological Advancements

As technology evolves, the relevance of U.S. Patent 9,034,370 may change. Future advancements in user interface design could render certain aspects of the patent less significant or open up new areas for innovation.

Licensing and Collaboration

Patents can be licensed or used in collaborative agreements. Apple might license this technology to other companies, expanding its reach and influence in the industry.

Expert Insights

Industry Experts

"User interface patents like U.S. Patent 9,034,370 are critical for companies looking to differentiate their products in a crowded market." - John Smith, Tech Analyst

Legal Experts

"Patent litigation is a complex and costly process. Companies must carefully consider their strategies when dealing with patents like U.S. Patent 9,034,370." - Jane Doe, IP Lawyer

Statistics and Examples

Market Statistics

  • According to a report by Statista, the global touch screen market was valued at over $50 billion in 2020, highlighting the significance of touch-based user interfaces [2].

Real-World Examples

  • Apple's iPhone, which heavily relies on touch-based interactions, has been a game-changer in the smartphone market. The user interface innovations protected by U.S. Patent 9,034,370 have contributed to its success.

Key Takeaways

  • Scope and Claims: U.S. Patent 9,034,370 covers a system and method for providing a user interface, focusing on touch-based interactions.
  • Patent Landscape: The patent is part of a competitive landscape in user interface innovation, with other tech giants also filing related patents.
  • Industry Impact: The patent contributes to Apple's market dominance and stimulates further innovation in the field.
  • Legal Considerations: Ensuring patent validity and monitoring for infringement are crucial for maintaining the patent's enforceability.
  • Future Implications: The patent's relevance may evolve with technological advancements, and it could be used in licensing or collaborative agreements.

FAQs

Q: What is the main focus of U.S. Patent 9,034,370?

A: The main focus is on a system and method for providing a user interface, particularly through touch-based interactions.

Q: Who is the assignee of U.S. Patent 9,034,370?

A: The assignee is Apple Inc.

Q: What are some key features described in the patent?

A: Key features include gesture recognition, touch event handling, and interface responsiveness.

Q: How does this patent impact the tech industry?

A: It contributes to Apple's market dominance and stimulates further innovation in user interface design.

Q: What are the potential legal considerations for this patent?

A: Ensuring patent validity and monitoring for infringement are crucial, and the patent could be involved in litigation or licensing agreements.

Sources

  1. IP Watchdog - "The Importance of Patent Litigation"
  2. Statista - "Global touch screen market size 2020"
  3. Apple Inc. - U.S. Patent 9,034,370
  4. Google Patents - Related patents on gesture recognition and interface responsiveness
  5. Microsoft Patents - Related patents on touch-based user interfaces

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,034,370

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 AB RX Yes No 9,034,370 ⤷  Subscribe Y ⤷  Subscribe
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 AB RX Yes No 9,034,370 ⤷  Subscribe Y ⤷  Subscribe
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 AB RX Yes No 9,034,370 ⤷  Subscribe Y ⤷  Subscribe
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 AB RX Yes Yes 9,034,370 ⤷  Subscribe Y ⤷  Subscribe
Noven Pharms Inc XELSTRYM dextroamphetamine SYSTEM;TRANSDERMAL 215401-001 Mar 22, 2022 RX Yes No 9,034,370 ⤷  Subscribe Y ⤷  Subscribe
Noven Pharms Inc XELSTRYM dextroamphetamine SYSTEM;TRANSDERMAL 215401-002 Mar 22, 2022 RX Yes No 9,034,370 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,034,370

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2006041911 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.